News & Events

News and Events

2017

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery

August 22, 2017

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
SAN JOSE, Calif., Aug. 22, 2017—Teikoku Pharma USA, Inc. (Teikoku Pharma) today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 3-day dexmedetomidine transdermal patch, a novel drug delivery system with a non-opioid active moiety for the management of post-surgical pain. The preliminary results demonstrate that the patch provides effective pain control across several parameters and produced no unexpected safety events in a postoperative setting.

READ MORE

2016

Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula

September 6, 2016

SAN JOSE, Calif., September 6, 2016 -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell and distribute TPU's Docetaxel Injection, Non-Alcohol Formula in China.

READ MORE

Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula

February 2, 2016

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

READ MORE

2015

Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

December 28, 2015

San Jose, Calif., Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

READ MORE

Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula

October 15, 2015

Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. to market, sell, and distribute TPU’s Docetaxel Injection, Non-Alcohol Formula in the United States.

READ MORE